Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)
Uwe Platzbecker(National Center for Tumor Diseases), Valeria Santini(Azienda Ospedaliero-Universitaria Careggi), Elena Crisà(Candiolo Cancer Institute), Sophie Park(Centre Hospitalier Universitaire de Grenoble), Ana Alfonso Piérola(Istituti di Ricovero e Cura a Carattere Scientifico), Aristoteles Giagounidis(Marien Hospital Düsseldorf), Matteo Della Porta(University of Milan), Sebastian Grosicki(Medical University of Silesia), Thibault Comont(Institut universitaire du cancer de Toulouse Oncopole), Pellegrino Musto(Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari), Dominic Brauer(University Hospital Leipzig), Thomas Cluzeau(Centre Hospitalier Universitaire de Nice), Antonella Poloni(Marche Polytechnic University), Lionel Adès(Centre National de la Recherche Scientifique), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Raquel De Paz Arias(Hospital Universitario La Paz), Sophie Dimicoli Salazar(Hôpital Cardiologique du Haut-Lévêque)
Cited by 0
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k